Natera, Inc. $NTRA Shares Bought by Groupama Asset Managment

by · The Markets Daily

Groupama Asset Managment grew its stake in Natera, Inc. (NASDAQ:NTRA – Free Report) by 19.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,256 shares of the medical research company’s stock after acquiring an additional 15,072 shares during the quarter. Groupama Asset Managment’s holdings in Natera were worth $21,135,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. MidFirst Bank acquired a new position in Natera in the 4th quarter valued at about $523,000. Kera Capital Partners Inc. boosted its stake in shares of Natera by 21.7% during the 4th quarter. Kera Capital Partners Inc. now owns 1,659 shares of the medical research company’s stock worth $383,000 after purchasing an additional 296 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its stake in shares of Natera by 45.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 2,252 shares of the medical research company’s stock worth $516,000 after purchasing an additional 709 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Natera by 2,768,561.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 498,359 shares of the medical research company’s stock worth $114,170,000 after buying an additional 498,341 shares in the last quarter. Finally, Compound Planning Inc. raised its position in shares of Natera by 17.2% in the fourth quarter. Compound Planning Inc. now owns 2,524 shares of the medical research company’s stock valued at $578,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $193.74, for a total transaction of $594,781.80. Following the completion of the transaction, the chief financial officer owned 58,291 shares in the company, valued at approximately $11,293,298.34. This trade represents a 5.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 162,342 shares of company stock valued at $35,283,396 over the last 90 days. 5.05% of the stock is currently owned by insiders.

Natera Stock Performance

NTRA opened at $231.41 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company’s 50 day simple moving average is $207.79 and its 200 day simple moving average is $215.40. The stock has a market capitalization of $33.14 billion, a PE ratio of -141.97 and a beta of 1.56.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. William Blair began coverage on shares of Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. Evercore reiterated an “outperform” rating and issued a $270.00 price target on shares of Natera in a report on Friday, May 8th. Wells Fargo & Company increased their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Robert W. Baird set a $265.00 price objective on Natera in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.53.

View Our Latest Stock Analysis on NTRA

Natera Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Recommended Stories

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).